Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aprea Therapeutics Inc (NQ: APRE )

25.55 +1.11 (+4.56%)
Streaming Delayed Price Updated: 2:04 PM EST, Dec 3, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,147
Open 24.30
Bid (Size) 25.33 (1)
Ask (Size) 25.71 (7)
Prev. Close 24.44
Today's Range 23.94 - 25.59
52wk Range 19.67 - 53.11
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
From GlobeNewswire News Releases
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
From GlobeNewswire News Releases

Performance

YTD
-43.59%
-43.59%
1 Month
+18.04%
+18.04%
3 Month
-1.75%
-1.75%
6 Month
-3.78%
-3.78%
1 Year
+1.65%
+1.65%

More News

Read More
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
From GlobeNewswire News Releases
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
From GlobeNewswire News Releases
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
From GlobeNewswire News Releases
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
From GlobeNewswire News Releases
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
From GlobeNewswire News Releases
Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes
From GlobeNewswire News Releases
Aprea Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
From GlobeNewswire News Releases
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.